<DOC>
	<DOC>NCT00888511</DOC>
	<brief_summary>The trial is a phase II study of daily Tarceva combined with definitive radiotherapy in inoperable locally advanced non small cell lung cancer (stage IIB-IIIB). The objective of the phase II trial is to examine Tarceva concomitant with curatively intended irradiation 66 Gy (2 Gy x 33 F, 5 F per week).</brief_summary>
	<brief_title>Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Age ≥18 years Patients with histologically or cytologically documented diagnosis locally advanced NSCLC stage IIB to IIIB without pleural effusion Performance status ≤2 on the ECOG scale Serum bilirubin must be ≤1.5 upper limit of normal (ULN) ALAT ≤2 x ULN Able to comply with study and followup procedures Patients with reproductive potential must use effective contraception Written (signed) informed consent to participate in the study Any unstable systemic disease (including active infection, unstable angina, congestive heart failure, severe hepatic, renal, or metabolic disease) Any other malignancies within 5 years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer) Inability to take oral medication, or requirement of intravenous alimentation Nursing mothers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Lung cancer</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Tarceva</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Local-regionally advanced non-small cell lung cancer</keyword>
</DOC>